Evidence map›Paper›PMID 30262461›Full record

ArticleCancer research2018

CBP Modulates Sensitivity to Dasatinib in Pre-BCR

Jesús Duque-Afonso, Chiou-Hong Lin, Kyuho Han, David W Morgens, Edwin E Jeng, Ziming Weng, Johan Jeong, Stephen Hon Kit Wong, Li Zhu, Michael C Wei and 8 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Wnt Signaling in Leukemia and Its Bone Marrow Microenvironment.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 2 countries.

Jesús Duque-Afonso *Department of Pathology, Stanford University School of Medicine, Stanford, California.
Chiou-Hong Lin *Department of Pathology, Stanford University School of Medicine, Stanford, California.
Kyuho HanDepartment of Genetics, Stanford University School of Medicine, Stanford, California.
David W MorgensDepartment of Genetics, Stanford University School of Medicine, Stanford, California.
Edwin E JengDepartment of Genetics, Stanford University School of Medicine, Stanford, California.
Ziming WengDepartment of Pathology, Stanford University School of Medicine, Stanford, California.
Johan JeongDepartment of Pathology, Stanford University School of Medicine, Stanford, California.
Stephen Hon Kit WongDepartment of Pathology, Stanford University School of Medicine, Stanford, California.
Li ZhuDepartment of Pathology, Stanford University School of Medicine, Stanford, California.
Michael C WeiDepartment of Pediatrics, Stanford University School of Medicine, Stanford, California.
Hee-Don ChaeDepartment of Pediatrics, Stanford University School of Medicine, Stanford, California.
Martin SchrappeDepartment of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Gunnar CarioDepartment of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Justus DuysterDepartment of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany.
Xiangshu XiaoDepartment of Physiology and Pharmacology, Oregon Health and Science University, Portland, Oregon.
Kathleen M SakamotoDepartment of Pediatrics, Stanford University School of Medicine, Stanford, California.
Michael C BassikDepartment of Genetics, Stanford University School of Medicine, Stanford, California.
Michael L ClearyDepartment of Pathology, Stanford University School of Medicine, Stanford, California. mcleary@stanford.edu.
Stanford Medicine · USStanford University · USUniversity Hospital Schleswig-Holstein · DEUniversity Medical Center Freiburg · DEOregon Health & Science University · US

Funding

Spectrum Stanford Center for clinical and Translational Research and EducationUL1TR001085 · NCATS · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD, GREENBERG, HARRY BERNARD · 2013 to 2017
$37.1M
Functional and Translational Epigenomics of Acute Lymphoblastic LeukemiaR01CA214888 · NCI · STANFORD UNIVERSITY · PI CLEARY, MICHAEL L · 2018 to 2023
$1.8M
NCATS NIH HHS UL1 TR001085NCI NIH HHS R01 CA214888
6 · The paper itself

Abstract

Dasatinib is a multi-tyrosine kinase inhibitor approved for treatment of Ph

Indexed as

Drug Resistance, NeoplasmAntineoplastic AgentsApoptosisbeta CateninCell CycleCell Line, TumorCREB-Binding ProteinDasatinibDrug Screening Assays, AntitumorGene Expression Regulation, LeukemicHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositivePrecursor Cell Lymphoblastic Leukemia-LymphomaProtein BindingProtein DomainsProtein Kinase InhibitorsAntineoplastic Agentsbeta CateninCREB-Binding ProteinCREBBP protein, humanCTNNB1 protein, humanDasatinibProtein Kinase InhibitorsPyrimidinesRNA, Small Interfering

Identifiers

PMID30262461
PMCPMC6283070
OpenAlexW2893391836

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.